Iantrek raises $23 million Series B

Iantrek said on August 30, 2022 that it had closed a $23 million Series B financing to support the U.S. rollout of its micro-interventional glaucoma surgery devices. The White Plains, New York-based company said the round was oversubscribed and led by Visionary Ventures and Sectoral Asset Management, with proceeds earmarked for clinical introduction and post-marketing studies in the United States. Ophthalmology Times reported the financing on August 31, 2022, citing the company’s announcement. The company also said its first U.S. cases using suprachoroidal technology had been performed earlier that month. That detail matters because it shows the financing was announced alongside an initial clinical rollout rather than before any U.S. use. Iantrek said it would present long-term clinical outcomes later that year at the American Academy of Ophthalmology meeting in Chicago, which was scheduled to begin on September 30, 2022. (ophthalmologytimes.com) ### Who put up the money, and who got board seats? Visionary Ventures and Sectoral Asset Management led the round, according to Iantrek’s announcement. The company said Marc-Andre Marcotte, a partner at Sectoral Asset Management, and Farrell Tyson, a general partner at Visionary Ventures, would join its board of directors. (ophthalmologytimes.com) The financing was described by Iantrek as oversubscribed. The company did not disclose a valuation in the materials reviewed. ### What exactly is Iantrek developing? Iantrek said the capital would support development and studies for its micro-interventional glaucoma surgical devices, often grouped under the MIGS label. (ophthalmologytimes.com) The company said its platform was designed to address two aqueous outflow pathways — trabecular and suprachoroidal — and described itself at the time as the only MIGS company with FDA-registered technologies aimed at both. Earlier in 2022, the company unveiled its CycloPen micro-interventional system targeting the suprachoroidal outflow pathway. In its announcement, Iantrek described that pathway as an established therapeutic target and said prior MIGS micro-stent interventions had shown sustained outflow enhancement, with a majority of patients achieving intraocular pressure reduction of 20% or more. That efficacy language came from the company’s release. (ophthalmologytimes.com) ### Why was the suprachoroidal detail highlighted? The first U.S. procedures were tied to Iantrek’s suprachoroidal approach, which targets one of the eye’s natural outflow pathways for aqueous fluid. In glaucoma treatment, lowering intraocular pressure is the central goal, and MIGS devices are marketed as less invasive alternatives to more traditional glaucoma surgery. (ophthalmologytimes.com) Ophthalmology Times said the company’s U.S. cases had taken place earlier in August 2022. The same report said Iantrek planned to share longer-term clinical results at the AAO meeting in Chicago later that year. ### What else changed at the company with the financing? Sean Ianchulev, Iantrek’s founder and chairman, was appointed chief executive alongside the financing announcement. (ophthalmologytimes.com) The company also named Jason Cha as vice president of sales and marketing and Ginger Clasby as head of clinical operations and regulatory. Cha had previously worked on the launch of the Hydrus Microstent at Ivantis, while Clasby had led regulatory approval work on the CyPass Microstent at Transcend Medical before both companies were acquired by Alcon, Iantrek said. ### What happened after that 2022 round? Iantrek’s current news page shows the company later raised a $42 million Series C on August 20, 2025 and has since reported additional U.S. procedural and clinical milestones tied to its glaucoma technologies. (ophthalmologytimes.com) The same page shows Adam Szaronos was appointed chief executive on February 4, 2025, succeeding Ianchulev in that role while Ianchulev remained involved with the company. The next dated milestone after the 2022 Series B was Iantrek’s planned presentation of long-term clinical outcomes at the AAO meeting in Chicago beginning September 30, 2022, according to the company and Ophthalmology Times. (ophthalmologytimes.com) (iantrekmed.com)